CompanyKROSNasdaqLexington, MA

Keros Therapeutics, Inc.

Keros Therapeutics develops protein therapeutics targeting TGF-β signaling for skeletal muscle, bone, and blood disorders.

SEC EDGAR ClinicalTrials.gov kerostx.com

8-KSep 29Latest SEC filing

Sep 28Latest story

September 2026

Keros doses first patient in Phase 2 trial of rinvatercept for Duchenne muscular dystrophy

Sep 28Clinical readoutKeros Therapeutics, Inc.rinvatercept

August 2026

Keros reports second-quarter 2026 results as Phase 2 rinvatercept DMD trial gets underway

Aug 3Quarterly updateKeros Therapeutics, Inc.rinvatercept

July 2026

Keros Therapeutics CFO Keith Regnante resigns, interim replacement named

Jul 22PeopleKeros Therapeutics, Inc.

Keros lists Phase 2 trial of KER-065 in Duchenne muscular dystrophy on ClinicalTrials.gov

Jul 15Trial updateKeros Therapeutics, Inc.rinvatercept